Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

Related Articles by Review for PubMed (Select 19136546)

1.

Daclizumab in treatment of multiple sclerosis patients.

Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ.

Mult Scler. 2009 Feb;15(2):272-4. doi: 10.1177/1352458508097468. Epub 2009 Jan 9.

PMID:
19136546
2.

Spotlight on anti-CD25: daclizumab in MS.

Schippling DS, Martin R.

Int MS J. 2008 Sep;15(3):94-8. Review.

PMID:
18808743
3.

Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

Martin R.

Clin Immunol. 2012 Jan;142(1):9-14. doi: 10.1016/j.clim.2011.10.008. Epub 2011 Nov 9. Review.

PMID:
22284868
4.

Daclizumab for relapsing remitting multiple sclerosis.

Liu J, Wang L, Zhan S, Tan J, Xia Y.

Cochrane Database Syst Rev. 2010 Jun 16;(6):CD008127. doi: 10.1002/14651858.CD008127.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD008127.

PMID:
20556791
5.

Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.

Reardon J, Perumal JS.

Drug Des Devel Ther. 2013 Oct 9;7:1187-93. doi: 10.2147/DDDT.S27766. eCollection 2013. Review.

6.

The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.

Milo R.

Ther Adv Neurol Disord. 2014 Jan;7(1):7-21. doi: 10.1177/1756285613504021. Review.

7.

Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.

Wiseman LR, Faulds D.

Drugs. 1999 Dec;58(6):1029-42. Review. Erratum in: Drugs 2000 Mar;59(3):476.

PMID:
10651389
8.

Daclizumab therapy for multiple sclerosis.

Bielekova B.

Neurotherapeutics. 2013 Jan;10(1):55-67. doi: 10.1007/s13311-012-0147-4. Review.

9.

Daclizumab treatment for multiple sclerosis.

Kim SE.

Pharmacotherapy. 2009 Feb;29(2):227-35. doi: 10.1592/phco.29.2.227. Review.

PMID:
19170591
10.

[Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].

Madsen M, Svendsen UG.

Ugeskr Laeger. 2000 Oct 16;162(42):5648-52. Review. Danish.

PMID:
11059309
11.

Spotlight on alemtuzumab.

Jones JL, Coles AJ.

Int MS J. 2009 Sep;16(3):77-81. Review.

PMID:
19878629
12.

Daclizumab (anti-CD25) in multiple sclerosis.

Pfender N, Martin R.

Exp Neurol. 2014 Dec;262 Pt A:44-51. doi: 10.1016/j.expneurol.2014.04.015. Epub 2014 Apr 24. Review.

PMID:
24768797
13.

[2012: Update on diagnosis and treatment of multiple sclerosis].

Havla J, Kümpfel T, Hohlfeld R.

Dtsch Med Wochenschr. 2012 Apr;137(17):894-9. doi: 10.1055/s-0032-1304927. Epub 2012 Apr 10. Review. German. No abstract available. Erratum in: Dtsch Med Wochenschr. 2012 May;137(20):1072.

PMID:
22492476
14.

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

Wiendl H, Gross CC.

Nat Rev Neurol. 2013 Jul;9(7):394-404. doi: 10.1038/nrneurol.2013.95. Epub 2013 Jun 4. Review.

PMID:
23732529
15.

[Therapeutic indications targeting etiology. (With the exception of primary progressive forms)].

Brassat D.

Rev Neurol (Paris). 2001 Sep;157(8-9 Pt 2):1014-28. Review. French.

PMID:
11787332
16.

Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?

Van Gelder T, Warlé M, Ter Meulen RG.

Drugs. 2004;64(16):1737-41. Review.

PMID:
15301558
17.

Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.

Martin R.

Neurodegener Dis. 2008;5(1):23-6. Review.

PMID:
18075271
18.
19.
20.

[Development of new therapies for multiple sclerosis].

Holmøy T, Celius EG.

Tidsskr Nor Laegeforen. 2011 May 6;131(8):832-6. doi: 10.4045/tidsskr.10.0077. Review. Norwegian.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk